Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 9/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22200378 | 0.90 | ERN1 (0.34) | ERN1 | |
| SCHEMBL22200653 | 0.88 | MTOR (0.38) | MTORRORCPIK3CA | |
| SCHEMBL22200424 | 0.88 | MTOR (0.37) | MTORRORCPIK3CA | |
| SCHEMBL25034241 | 0.84 | ERN1 (0.36) | MTORRORCPIK3CDPIK3R1PIK3CA | |
| SCHEMBL22200601 | 0.79 | ERN1 (0.43) | MTORPIK3CDPIK3CAERN1 | |
| SCHEMBL22200792 | 0.78 | MTOR (0.35) | MTORRORCPIK3CA | |
| SCHEMBL22200825 | 0.75 | CYP1A2 (0.36) | MTORRORC | |
| SCHEMBL22200739 | 0.75 | BTK (0.43) | MTORPIK3CA | |
| SCHEMBL25034228 | 0.74 | FEN1 (0.39) | MTORRORCPIK3CA | |
| SCHEMBL22200802 | 0.74 | MTOR (0.41) | MTORPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020142612-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. | GENENTECH, INC. (US) | 2020-07-09 | — | — | WO | disclosed |